Literature DB >> 17719271

LV systolic impairment in patients with asymptomatic coronary heart disease and type 1 diabetes is related to coronary atherosclerosis, glycaemic control and advanced glycation endproducts.

Kjetil Steine1, Jakob R Larsen, Marie Stugaard, Tore Julsrud Berg, Magne Brekke, Knut Dahl-Jørgensen.   

Abstract

AIMS: To evaluate whether heart failure in type 1 diabetes is linked to poor glycaemic control, coronary atherosclerosis or advanced glycation endproducts (AGEs).
METHODS: Twenty six patients with type 1 diabetes (mean duration 32+/-5 years), and 16 age matched controls were recruited. Mean HbA(1c) through 18 years (HbA(1c)18), serum levels of AGEs and coronary atherosclerotic burden (CAB) were determined by IVUS. Peak tissue velocities and strain by tissue Doppler imaging were measured in 12 LV regions as an evaluation of LV function.
RESULTS: Systolic tissue velocity was inversely correlated to CAB (r=0.53, p<0.01), to HbA(1c)18 (r=0.46, p<0.05) and to the duration of diabetes (r=0.46, p<0.05). Systolic strain was inversely correlated to HbA(1c)18 (r=0.45, p<0.05), to duration of diabetes (r=0.41, p<0.05), and tended to correlate with AGEs (r=0.37, p=0.07). In multiple regression analyses, CAB and HbA(1c)18 were significant independent predictors for systolic velocity, while AGEs and duration of diabetes were significant predictors of systolic strain.
CONCLUSION: LV systolic function was impaired by increasing coronary atherosclerosis and worsening of glycaemic control. AGEs might be another mechanism for the increased risk of heart failure in type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17719271     DOI: 10.1016/j.ejheart.2007.07.013

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  7 in total

Review 1.  Does accumulation of advanced glycation end products contribute to the aging phenotype?

Authors:  Richard D Semba; Emily J Nicklett; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-17       Impact factor: 6.053

2.  Advanced glycation end products in myocardial reperfusion injury.

Authors:  Peter Celec; Július Hodosy; Peter Jáni; Pavol Janega; Matúš Kúdela; Marta Kalousová; Johana Holzerová; Vojtech Parrák; Lukáč Halčák; Tomáš Zima; Martin Braun; Ivan Pecháň; Ján Murín; Katarína Šebeková
Journal:  Heart Vessels       Date:  2011-05-12       Impact factor: 2.037

3.  Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress.

Authors:  Jianfei Chen; Minbao Song; Shiyong Yu; Pan Gao; Yang Yu; Hong Wang; Lan Huang
Journal:  Mol Cell Biochem       Date:  2009-09-15       Impact factor: 3.396

4.  Role of advanced glycation end products in cardiovascular disease.

Authors:  Zeinab Hegab; Stephen Gibbons; Ludwig Neyses; Mamas A Mamas
Journal:  World J Cardiol       Date:  2012-04-26

5.  Advanced glycation end products reduce the calcium transient in cardiomyocytes by increasing production of reactive oxygen species and nitric oxide.

Authors:  Zeinab Hegab; Tamer M A Mohamed; Nicholas Stafford; Mamas Mamas; Elizabeth J Cartwright; Delvac Oceandy
Journal:  FEBS Open Bio       Date:  2017-09-26       Impact factor: 2.693

Review 6.  The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review.

Authors:  Sarah Louise Fishman; Halis Sonmez; Craig Basman; Varinder Singh; Leonid Poretsky
Journal:  Mol Med       Date:  2018-11-23       Impact factor: 6.354

Review 7.  Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes.

Authors:  Ping Yang; Jian Feng; Qing Peng; Xing Liu; Zhongcai Fan
Journal:  Oxid Med Cell Longev       Date:  2019-12-06       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.